Associated tags: Therapy, Nutcracker, RNA, Biotechnology, Health, Science, Genetics, Oncology, Pharmaceutical, Research, Vaccine, University, Clinical Trials, Pharmaceutical industry, Patient, HPV, Neoplasm, Messenger
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA, SAN FRANCISCO
Software,
Research,
Men,
Pharmaceutical,
Oncology,
Consumer,
Technology,
Genetics,
Clinical Trials,
Science,
Biotechnology,
Health,
PSMA,
CD3,
University,
WT,
STEAP1,
RNA,
Tumor microenvironment,
Protein engineering,
Prostate cancer,
Engineering,
HVEM,
Patient,
Cervical intraepithelial neoplasia,
Toxicity,
Messenger,
Beauty,
AACR,
Therapy,
Vaccine Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.
Key Points:
- Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.
- LIGHT comes in two forms: membrane-bound or soluble, with the former generally having stronger activity, leading to the hypothesis that limiting membrane shedding would enhance advantageous activity.
- Nutcracker’s scientists engineered multiple variants of LIGHT with either flexible or rigid linkers in place of protease-sensitive sites, to explore how membrane shedding susceptibility affects immunomodulatory activity.
- Of the tested designs, membrane-stabilized variants of LIGHT enhanced HVEM stimulation over WT LIGHT and increased proinflammatory cytokines in the tumor microenvironment.
Oncology,
Health,
Genetics,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Online,
Toxicity,
Nutcracker,
Prostate cancer,
RNA,
Cervical intraepithelial neoplasia,
Abstract,
AACR,
Therapy,
Antigen The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.
Key Points:
- The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.
- The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470.
- This therapy is designed to target prostate cancer antigens with mRNA-encoded, multi-specific T cell engagers with a strong anti-tumor effect and low toxicity.
- The 2024 AACR Annual Meeting takes place in San Diego from April 5-10.
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Genetics,
Clinical Trials,
RNA,
Geneva University Hospitals,
University,
Messenger,
Lawrence Berkeley National Laboratory,
Joint Genome Institute,
DNA,
Therapy,
Genomics,
World Health Organization,
Growth,
CSO,
Molecular medicine,
Synthetic biology Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).
Key Points:
- Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).
- “I’m thrilled to assume my new role, and to continue leading Nutcracker’s research team through a new era of growth and innovation,” said Dr. Deutsch.
- Before joining Nutcracker, Dr. Deutsch was a research scientist at Lawrence Berkeley Lab and led the DNA synthesis foundry at the Joint Genome Institute.
- “Sam has brought invaluable experience and leadership to Nutcracker since its establishment in 2018,” said Igor Khandros, CEO.
Retrieved on:
Tuesday, November 7, 2023
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Genetics,
Clinical Trials,
Neoplasm,
Human papillomavirus infection,
Cervical cancer,
Mouse,
Anemia,
CIN,
Therapy,
RNA,
HPV,
Cervical intraepithelial neoplasia,
CD47,
Immortalised cell line,
Cell,
Protein,
Engineering,
SITC,
Immunotherapy,
HPV16,
Messenger,
Animal,
Society,
Alpha globulin,
Patient,
Vivo,
Vaccine,
Nutcracker These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
Key Points:
- These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
- Anemia is the most common adverse effect of CD47-targeting molecules, since red blood cells also express CD47.
- Moreover, modifying the RNA sequence of the prospective anti-CD47 molecule is far more efficient than engineering the final protein product.
- Our platform has made it possible for Nutcracker to lay a strong and early foundation for our future therapeutic work.”
Retrieved on:
Tuesday, October 24, 2023
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Genetics,
Clinical Trials,
Cancer,
RNA,
Nutcracker,
HPV,
EST,
CD47,
Immunotherapy,
Conference,
Journal,
SITC,
JITC,
Neoplasm,
IL-12,
Abstract,
Messenger,
Society,
Therapy,
CCR4,
Vaccine These data will be presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.
Key Points:
- These data will be presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, CA, from November 1 through 5, 2023.
- Title: mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory
Poster presentations will be accessible in person and virtually.
- All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on October 31 at 9:00 a.m. EST.
- For more information about SITC 2023, please visit https://www.sitcancer.org/home .
Health,
Genetics,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
CRISPR,
Panavally,
University,
GE HealthCare,
Draper Laboratory,
Collins,
Human Longevity,
Clinical trial,
Business,
Longevity,
ARCH Venture Partners,
RNA,
David G. Booth,
University of Illinois Urbana-Champaign,
Editas Medicine,
Global Oncology,
Baxter International,
Therapy,
Beckman Coulter,
CERT,
Pharmaceutical industry,
Science,
Microbiology,
Nutcracker Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Cynthia Collins to the company’s board of directors.
Key Points:
- Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Cynthia Collins to the company’s board of directors.
- Collins joins Nutcracker Therapeutics with more than four decades of experience working in the pharmaceutical and biotech industry.
- Additionally, she is a board member of Poseida Therapeutics (PSTX), Certara (CERT), DermTech (DMTK), Draper Laboratories and Triumvira Immunologics.
- “We are delighted to welcome Cindy to the board,” says Igor Khandros, Ph.D., CEO of Nutcracker Therapeutics.
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
Genetics,
Nutcracker,
Therapy,
RNA,
Nutshell,
Messenger,
Oligonucleotide,
Vaccine Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA.
Key Points:
- Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA.
- Nutcracker Therapeutics has developed its Nutshell™ platform of peptoid delivery vehicles for use with its mRNA therapies.
- This unique class of structurally-tunable peptoids contains both a hydrophobic domain and an amino-functionalized cationic domain to self-assemble with mRNA cargos, enabling the safe and effective delivery of mRNA for Nutcracker’s therapeutic programs.
- “We have taken some of the most difficult challenges in mRNA therapeutic delivery head on, building our Nutshell delivery solution to complement our therapeutic programs and round out our end-to-end drug development process,” remarked Chief Executive Officer Igor Khandros, Ph.D. “Through our differentiated nanoparticle approach, we look to overcome hurdles of chemical instability, innate immunogenicity, and inefficient in vivo delivery to fully realize RNA’s clinical potential.”
Retrieved on:
Wednesday, April 19, 2023
Oncology,
Health,
Genetics,
Research,
Science,
Pharmaceutical,
Biotechnology,
CIN,
AACR,
CD1D,
University,
HPV16,
RNA,
Messenger,
E7,
Cervical cancer,
Patient,
Antigen presentation,
Nutcracker,
HPV,
Neoplasm,
Cervical intraepithelial neoplasia,
Therapy,
Tumor microenvironment,
Human papillomavirus infection,
Prostate cancer,
Pharmaceutical industry,
Vaccine,
DRS Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
Key Points:
- Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
- The lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated.
- More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.
- Lawrence Fong and David Oh at the University of California, San Francisco — which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.
Science,
Biotechnology,
Research,
Pharmaceutical,
Human Resources,
Oncology,
Health,
Professional Services,
Culture,
Nutcracker,
Thermo Fisher Scientific,
Medivation,
CHRO,
Therapy,
University of Notre Dame,
University of California, Berkeley,
HR,
Peters,
Patient,
University,
Genomics,
RNA,
Marketing,
Management,
Standard BioTools,
Pfizer Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO).
Key Points:
- Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO).
- “I am particularly excited to come aboard at this important inflection point for the company, as it unlocks the powerful potential of RNA therapeutics.
- “Angela brings extensive experience, alongside a proven track record of elevating and transforming internal operations across the biotech industry,” said Igor Khandros, CEO.
- Peters joins several other key C-suite hires within the past year, including Chief Medical Officer Dr. Robert Schott, Chief Operating Officer Dr. John Stubenrauch, and Chief Business Officer Dr. Geoff Nosrati.
Research,
Genetics,
Clinical Trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Wedbush Securities,
ARCH Venture Partners,
Clinical trial,
RNA,
University,
Therapy,
Faculty,
Pharmaceutical industry,
Nutcracker Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors.
Key Points:
- Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors.
- Dr. Dietz brings to Nutcracker Therapeutics nearly three decades of experience in the investment banking and pharmaceutical industries.
- "Dr. Dietz will be a welcome addition to our board," said Igor Khandros, Ph.D., CEO of Nutcracker Therapeutics.
- He joins Dr. Khandros, Robert Nelsen of ARCH Venture Partners and Michael Bigham of Paratek Pharmaceuticals on Nutcracker Therapeutics’ board of directors.
